Phosphodiesterase 4 inhibitor

Ensifentrine is a novel inhaled selective dual phosphodiesterase-3 (PDE3) and phosphodiesterase-4 (PDE4) inhibitor that is now approved in the United States for

Ohtuvayre (ensifentrine) is a phosphodiesterase 3 (PDE3) inhibitor and phosphodiesterase 4 (PDE4) inhibitor indicated for the maintenance treatment of chronic

Efficacy and safety of RPL554, a dual phosphodiesterase 3 and phosphodiesterase 4 inhibitor, in healthy volunteers and in patients with asthma or chronic

A phosphodiesterase-4 inhibitor, commonly referred to as a PDE4 inhibitor, is a drug used to block the degradative action of phosphodiesterase 4 (PDE4) on cyclic adenosine

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice PLoS One, 8 ( 2025 ), Article e

Phosphodiesterase Type 4 Inhibitors, Phosphodiesterase Type 5 Inhibitors For brand name drugs under review and drug reviews completed on or before

Phosphodiesterase inhibitors (PDE inhibitors) are a class of drugs that inhibit phosphodiesterase enzymes (PDE enzymes). Mechanism of action Desired effect; Nonspecific phosphodiesterase inhibitors (inhibitors of PDE3, 4, and 5) Theophylline (methylxanthines) COPD (severe and refractory cases)

Phosphodiesterase (PDE) 4 Inhibitors Overview/Summary Daliresp (roflumilast) is an oral phosphodiesterase (PDE) 4 inhibitor Food and Drug Administration (FDA)-approved

Phosphodiesterase-4 Inhibitors. Upregulation of phosphodiesterase-4, the enzyme responsible for degradation of cAMP, is thought to play a role in the loss of effect of β nists. Roflumilast